Gastrointestinal Cancer | Topics

 
Frontline Regorafenib Plus Pembrolizumab Reveals Antitumor Activity in HCC
June 10, 2021

Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.

Toripalimab and HAIC Plus Lenvatinib Produced Durable Responses in Advanced HCC
June 09, 2021

Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.

Infigratinib Granted Accelerated Approval for FGFR2+ Cholangiocarcinoma
May 29, 2021

Objective response data from a phase 2 trial supported the FDA’s decision to grant infigratinib accelerated approval to treat patients with certain a certain type of cholangiocarcinoma.